Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial

Gynecologic Oncology

Volumn 117, Issue 2, 2010, Pages 276-280

  Fabbro, M ^a   Gladieff, L ^b   Guichard, F ^c   El Demery, M ^d   Dalenc, F ^e   Kerr, C ^a   Delannes, M ^e   Paraiso, D ^f   Pujade Lauraine, E ^g   Kurtz, J E ^h  

^a CENTRE VAL D AURELLE   (France)

^b Centre de Lutte contre le Cancer   (France)

^c Polyclinique Bordeaux Nord   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f Centre Hospitalier de l'Agglomeration Montargeoise   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Cervix cancer; Chemoradiation; Irinotecan; Phase I clinical trial

Indexed keywords

CISPLATIN; IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; NAUSEA; NEUROPATHY; PELVIS PAIN SYNDROME; PELVIS RADIOGRAPHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CAMPTOTHECIN; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 77950300850     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.027     Document Type: Article

References (28)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55 2 (2005 Mar-Apr) 74-108
2. Devesa S.S., Silverman D.T., Young Jr. J.L., Pollack E.S., Brown C.C., Horm J.W., et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J. Natl. Cancer Inst. 79 4 (1987 Oct) 701-770
3. Perez C.A., Grigsby P.W., Chao K.S., Mutch D.G., and Lockett M.A. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int. J. Radiat. Oncol. Biol. Phys. 41 2 (1998 May 1) 307-317 Erratum in: Int J Radiat Oncol Biol Phys 1999 Nov 1;45(4):1093
4. Omura G.A. Chemotherapy for stage IVB or recurrent cancer of the uterine cervix. J. Natl. Cancer Inst. Monogr. 21 (1996) 123-126
5. Dolling J.A., Boreham D.R., Brown D.L., Mitchel R.E., and Raaphorst G.P. Modulation of radiation-induced strand break repair by cisplatin in mammalian cells. Int. J. Radiat. Biol. 74 1 (1998 Jul) 61-69
6. Wallner K.E., and Li G.C. Effect of cisplatin resistance on cellular radiation response. Int. J. Radiat. Oncol. Biol. Phys. 13 4 (1987 Apr) 587-591
7. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 15 (1999 Apr 15) 1137-1143
8. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler Jr. W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 5 (1999 May) 1339-1348
9. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 15 (1999 Apr 15) 1144-1153
10. Peters III W.A., Liu P.Y., Barrett II R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18 8 (2000 Apr) 1606-1613 Erratum in: N Engl J Med 1999 Aug 26;341(9):708
11. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs III C.L., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340 15 (1999 Apr 15) 1154-1161
12. Green J., Kirwan J., Tierney J., Vale C., Symonds P., Fresco L., et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst. Rev. 20 3 (2005 Jul) CD002225
13. Rose P.G. Combined-modality therapy of locally advanced cervical cancer. J. Clin. Oncol. 21 10 Suppl (2003 May 15) 211s-217s
14. Choy H., and MacRae R. Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology 7 supplement 8 (2001) 22-28 (Williston Park) Review
15. Look K.Y., Blessing J.A., Levenback C., Kohler M., Chafe W., et al. Phase II trial of CPT-11 in recurrent squamous cell carcinoma of cervix: a gynaecologic oncology group study. Gynecol. Oncol. 70 3 (1998 Sep) 334-338
16. Verschraegen C.F., Levy T., Kudelka A.P., Llerena E., Ende K., et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J. Clin. Oncol. 15 2 (1997 Feb) 625-631
17. Chitapanarux I., Tonusin A., Sukthomya V., Charuchinda C., Pukanhapan N., et al. Phase II clinical study of irinotecan and cisplatin as first line chemotherapy in metastatic and recurrent cervical cancer. Gynecol. Oncol. 89 3 (2003 Jun) 402-407
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000 Feb 2) 205-216
19. Walker J.L., Morrison A., DiSilvestro P., von Gruenigen V.E., and Gynecologic Oncology Group. A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study. Gynecol. Oncol. 112 1 (2009 Jan) 78-84
20. Alvarez E.A., Wolfson A.H., Pearson J.M., Crisp M.P., Mendez L.E., Lambrou N.C., et al. A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer. Gynecol. Oncol. 113 2 (2009 May) 195-199
21. Long III H.J., Bundy B.N., Grendys Jr. E.C., Benda J.A., McMeekin D.S., Sorosky J., et al., Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23 21 (2005 Jul 20) 4626-4633
22. Pearcey R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 20 4 (2002 Feb 15) 966-972
23. Moore D.H. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J. Natl. Compr. Cancer Netw. 6 (2008) 53-57
24. Choi I.J., Cha M.S., Park E.S., Han M.S., Choi Y., Je G.H., et al. The efficacy of concurrent cisplatin and 5-flurouracil chemotherapy and radiation therapy for locally advanced cancer of the uterine cervix. J. Gynecol. Oncol. 19 2 (2008 Jun) 129-134
25. Oka M., Fukuda M., Kuba M., et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur. J. Cancer 38 (2002) 1998-2004
26. Oka M., Fukuda M., Fukuda M., et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer. Eur. J. Cancer 37 (2001) 1359-1365
27. Rothenberg M.L., Kuhn J.G., Burris H.A., et al. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11 (1993) 2194-2204
28. Irvin W.P., Price F.V., Bailey H., et al. A phase II study of Irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 82 (1998) 328-333